Judge orders Boehringer to disclose Humira biosimilar plans

28-02-2019

Judge orders Boehringer to disclose Humira biosimilar plans

360b / Shutterstock.com

A US judge has ordered Boehringer Ingelheim to release its rollout plans for a biosimilar version of Humira (adalimumab), following a request from AbbVie.


AbbVie, patent, patent infringement, Boehringer Ingelheim, Humira, BPCIA, biologics, arthritis, biosimilars

LSIPR